CD3high and FoxP3- tumor-infiltrating lymphocytes in the invasive margin as a favorable prognostic marker in patients with invasive urothelial carcinoma of the bladder

被引:0
作者
Sun, Zi-Jun [1 ]
Zhao, Jing-Wen [2 ]
Zhao, Ming [3 ]
Chen, Yuan [3 ]
Zhang, Xin [3 ]
Li, Hai-Chang [2 ]
Wu, Guo-Qing [4 ]
Zhang, Da-Hong [1 ,5 ,6 ]
机构
[1] Qingdao Univ, Zhejiang Prov Peoples Hosp, Dept Urol, Qingdao, Shandong, Peoples R China
[2] Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China
[3] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Dept Pathol, Hangzhou, Peoples R China
[4] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Dept Oncol, Hangzhou, Peoples R China
[5] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Dept Urol, Hangzhou, Zhejiang, Peoples R China
[6] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Dept Urol, 158 Shang Tang Rd, Hangzhou 310014, Peoples R China
关键词
bladder cancer; CD3; CD4; CD8; FoxP3; invasive urothelial carcinoma of the bladder; prognosis; tumor-infiltrating lymphocytes; REGULATORY T-CELLS; CISPLATIN-INELIGIBLE PATIENTS; CANCER STATISTICS; SINGLE-ARM; MULTICENTER; SURVIVAL; CD4(+); SUBPOPULATIONS; PEMBROLIZUMAB; MELANOMA;
D O I
10.1097/CAD.0000000000001468
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor-infiltrating lymphocytes (TILs) have been extensively explored as prognostic biomarkers and cellular immunotherapy methods in cancer patients. However, the prognostic significance of TILs in bladder cancer remains unresolved. We evaluated the prognostic effect of TILs in bladder cancer patients. Sixty-four bladder cancer patients who underwent surgical resection between 2018 and 2020 in Zhejiang Provincial People's Hospital were analyzed in this study. Immunohistochemistry was used to evaluate CD3, CD4, CD8, and FoxP3 expression on TILs in the invasive margin of tumor tissue, and the presence of TIL subsets was correlated with the disease-free survival (DFS) of bladder cancer patients. The relationship between clinical-pathological features and DFS were analyzed. A high level of CD3(+)TILs (CD3(high)TILs) (P = 0.027) or negative expression of FoxP3 TILs (FoxP3(-) TILs) (P = 0.016) was significantly related to better DFS in bladder cancer patients. Those with CD3(high)FoxP3(-) TILs had the best prognosis compared to those with CD3(high)FoxP3(+) TILs or CD3(low)FoxP3(-) TILs (P = 0.0035). Advanced age [HR 4.57, (1.86-11.25); P = 0.001], CD3(low) TILs [HR 0.21, (0.06-0.71); P = 0.012], CD8(low) TILs [HR 0.34, (0.12-0.94); P = 0.039], and FoxP3(+) TILs [HR 10.11 (1.96-52.27); P = 0.006] in the invasive margin were associated with a worse prognosis (DFS) by multivariate analysis. In conclusion, we demonstrated that CD3(high), FoxP3(-), and CD3(high)FoxP3(-) TILs in the invasive margin were significantly associated with better DFS. CD8(high) and CD4(high) TILs in the invasive margin tended to predict better DFS in bladder cancer. Patients with CD4(high)CD8(high) TILs in the invasive margin were likely to have a better prognosis.
引用
收藏
页码:844 / 851
页数:8
相关论文
共 42 条
[1]   EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013 [J].
Babjuk, Marko ;
Burger, Maximilian ;
Zigeuner, Richard ;
Shariat, Shahrokh F. ;
van Rhijn, Bas W. G. ;
Comperat, Eva ;
Sylvester, Richard J. ;
Kaasinen, Eero ;
Boehle, Andreas ;
Palou Redorta, Joan ;
Roupret, Morgan .
EUROPEAN UROLOGY, 2013, 64 (04) :639-653
[2]   Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers [J].
Badoual, C ;
Hans, S ;
Rodriguez, J ;
Peyrard, S ;
Klein, C ;
Agueznay, NE ;
Mosseri, V ;
Laccourreye, O ;
Bruneval, P ;
Fridman, WH ;
Brasnu, DF ;
Tartour, E .
CLINICAL CANCER RESEARCH, 2006, 12 (02) :465-472
[3]   First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J].
Balar, Arjun V. ;
Castellano, Daniel ;
O'Donnell, Peter H. ;
Grivas, Petros ;
Vuky, Jacqueline ;
Powles, Thomas ;
Plimack, Elizabeth R. ;
Hahn, Noah M. ;
de Wit, Ronald ;
Pang, Lei ;
Savage, Mary J. ;
Perini, Rodolfo F. ;
Keefe, Stephen M. ;
Bajorin, Dean ;
Bellmunt, Joaquim .
LANCET ONCOLOGY, 2017, 18 (11) :1483-1492
[4]   Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].
Balar, Arjun V. ;
Galsky, Matthew D. ;
Rosenberg, Jonathan E. ;
Powles, Thomas ;
Petrylak, Daniel P. ;
Bellmunt, Joaquim ;
Loriot, Yohann ;
Necchi, Andrea ;
Hoffman-Censits, Jean ;
Perez-Gracia, Jose Luis ;
Dawson, Nancy A. ;
van der Heijden, Michiel S. ;
Dreicer, Robert ;
Srinivas, Sandy ;
Retz, Margitta M. ;
Joseph, Richard W. ;
Drakaki, Alexandra ;
Vaishampayan, Ulka N. ;
Sridhar, Srikala S. ;
Quinn, David I. ;
Duran, Ignacio ;
Shaffer, David R. ;
Eigl, Bernhard J. ;
Grivas, Petros D. ;
Yu, Evan Y. ;
Li, Shi ;
Kadel, Edward E., III ;
Boyd, Zachary ;
Bourgon, Richard ;
Hegde, Priti S. ;
Mariathasan, Sanjeev ;
Thastrom, AnnChristine ;
Abidoye, Oyewale O. ;
Fine, Gregg D. ;
Bajorin, Dean F. .
LANCET, 2017, 389 (10064) :67-76
[5]   Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].
Bellmunt, J. ;
de Wit, R. ;
Vaughn, D. J. ;
Fradet, Y. ;
Lee, J. -L. ;
Fong, L. ;
Vogelzang, N. J. ;
Climent, M. A. ;
Petrylak, D. P. ;
Choueiri, T. K. ;
Necchi, A. ;
Gerritsen, W. ;
Gurney, H. ;
Quinn, D. I. ;
Culine, S. ;
Sternberg, C. N. ;
Mai, Y. ;
Poehlein, C. H. ;
Perini, R. F. ;
Bajorin, D. F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026
[6]   2011: the immune hallmarks of cancer [J].
Cavallo, Federica ;
De Giovanni, Carla ;
Nanni, Patrizia ;
Forni, Guido ;
Lollini, Pier-Luigi .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (03) :319-326
[7]   Correlation between aryl hydrocarbon receptor and IL-17+ and Foxp3+ T-cell infiltration in bladder cancer [J].
Fattahi, Soheila ;
Karimi, Monireh ;
Ghatreh-Samani, Mahdi ;
Taheri, Fatemeh ;
Shirzad, Hedayatollah ;
Alibeigi, Faramarz Mohammad ;
Anjomshoa, Maryam ;
Bagheri, Nader .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2021, 102 (06) :249-259
[8]   Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection [J].
Gao, Qiang ;
Qiu, Shuang-Jian ;
Fan, Jia ;
Zhou, Jian ;
Wang, Xiao-Ying ;
Xiao, Yong-Sheng ;
Xu, Yang ;
Li, Yi-Wei ;
Tang, Zhao-You .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) :2586-2593
[9]   Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome [J].
Gobert, Michael ;
Treilleux, Isabelle ;
Bendriss-Vermare, Nathalie ;
Bachelot, Thomas ;
Goddard-Leon, Sophie ;
Arfi, Vanessa ;
Biota, Cathy ;
Doffin, Anne Claire ;
Durand, Isabelle ;
Olive, Daniel ;
Perez, Solene ;
Pasqual, Nicolas ;
Faure, Christelle ;
Coquard, Isabelle Ray ;
Puisieux, Alain ;
Caux, Christophe ;
Blay, Jean-Yves ;
Menetrier-Caux, Christine .
CANCER RESEARCH, 2009, 69 (05) :2000-2009
[10]   CD4+ follicular helper T cell infiltration predicts breast cancer survival [J].
Gu-Trantien, Chunyan ;
Loi, Sherene ;
Garaud, Soizic ;
Equeter, Carole ;
Libin, Myriam ;
de Wind, Alexandre ;
Ravoet, Marie ;
Le Buanec, Helene ;
Sibille, Catherine ;
Manfouo-Foutsop, Germain ;
Veys, Isabelle ;
Haibe-Kains, Benjamin ;
Singhal, Sandeep K. ;
Michiels, Stefan ;
Rothe, Francoise ;
Salgado, Roberto ;
Duvillier, Hugues ;
Ignatiadis, Michail ;
Desmedt, Christine ;
Bron, Dominique ;
Larsimont, Denis ;
Piccart, Martine ;
Sotiriou, Christos ;
Willard-Gallo, Karen .
JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (07) :2873-2892